What's Happening?
DemeRx, Inc. has been awarded a $1.7 million Small Business Innovation Research (SBIR) Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) at the NIH. The funding will support the development of DMX-1001, a neuroplastogen drug candidate for treating Alcohol Use Disorder (AUD). DMX-1001 targets multiple areas of the central nervous system, promoting neuroplasticity and reducing cravings. The drug has completed Phase 1b clinical trials, demonstrating safety and informing dose selection for Phase 2 trials.
Why It's Important?
Alcohol Use Disorder affects over 29 million Americans and is a leading cause of preventable death. Current treatments are limited, with high relapse rates. DMX-1001 offers a novel therapeutic approach, potentially transforming treatment options for AUD. By promoting neuroplasticity, the drug may reverse long-term effects of AUD and lower relapse risk. This development could significantly impact public health, providing a new solution for individuals seeking effective treatment.
What's Next?
DemeRx plans to advance DMX-1001 into Phase 2 clinical trials, focusing on patients with AUD. The company aims to leverage the NIH grant to further research and development, ultimately seeking to offer a transformative treatment option. Successful trials could lead to broader adoption of DMX-1001, addressing the urgent need for effective AUD therapies.
